EAST GERMAN FIRMS ASSERT THEMSELVES

12 April 1992

The 30 member companies of the eastern German section of the German drug industry association, the BPI, increased their share of the eastern German drug market to about 50% in 1991, but a slight loss of market share is expected this year, according to the BPI.

Total sales of the eastern German drug industry last year reached 1.7 billion Deutschemarks ($1 billion), of which 75% came from sales of drugs in the five eastern German states. This result was affected by the discount regulation which has been in force since April 1991 and which cut income by some 240 million marks. Half of the 30 companies have now been privatized.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight